TrumpRx.gov launches with GLP-1 coupons

The White House launched TrumpRx.gov on February 5, 2026, a federal website that points people with valid prescriptions to discounted cash prices on 40 branded medicines, including the most widely used GLP-1 drugs ^[1]. The launch covers products from the first five manufacturers that struck "most-favored-nation" pricing deals with the administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer ^[1].

For GLP-1s, the advertised reductions are large. According to the White House, the monthly price of Ozempic falls from $1,028 and injectable Wegovy from $1,349 to an average of $350 and as low as $199, depending on dose strength ^[1]. The Wegovy pill — an oral form of semaglutide — drops from $1,349 to as low as $149, again depending on strength ^[1]. Zepbound (tirzepatide) goes from $1,088 to an average of $346 and as low as $299 ^[1].

The fine print on "as low as"

The headline numbers are floor prices, not what everyone pays. Drug Topics, reporting from the TrumpRx site, says semaglutide pricing is tiered by dose: the lowest strength listed (0.25/0.5) is $199 and the highest (2/0.5) is $499 ^[2]. That outlet also reports the $199 price applies for the first two months before rising to $349 ^[2]. The White House fact sheet does not mention an introductory period or a $499 top-tier price; it describes $199 as the low end and $350 as the average ^[1]. The two sources are not in direct conflict, but the government summary leaves out the time limit and the upper end of the range.

How the discounts reach patients also varies. The White House says that depending on the manufacturer, patients can get savings through coupons they print or download to a phone, or through manufacturer-run channels built into the site ^[1]. A valid prescription is required ^[1].

Other listed prices include insulin lispro as low as $25 a month ^[1], a $35 monthly cap on Novo Nordisk insulin products ^[2], and steep cuts on fertility drugs: Gonal-F as low as $168 per pen, Cetrotide from $316 to $22.50, and Ovidrel from $251 to $84 ^[1].

Separately, Drug Topics reports that Medicare beneficiaries' out-of-pocket costs for semaglutide and tirzepatide are capped at a $50 monthly copay under the broader agreements, and that Medicare and Medicaid will be able to cover obesity medications ^[2]. That figure traces to a November 2025 White House fact sheet rather than to the TrumpRx launch itself ^[2].

Why it matters for patients

Most people taking semaglutide or tirzepatide have faced one of two bad options: navigate insurance prior authorization, or pay four figures a month. A government-hosted cash-price channel adds a third path, and for someone uninsured or with a plan that excludes obesity drugs, the difference between $1,349 and $199 to $499 is the difference between starting and not starting.

But cash prices are rarely a clean win. The advertised floors apply to specific dose strengths, and GLP-1 treatment usually involves moving up through strengths over time ^[2]. If the introductory rate is limited to two months as Drug Topics reports, the price a person pays in month six may look very different from the number on the homepage ^[2]. The sources do not say whether TrumpRx purchases count toward an insurance deductible or out-of-pocket maximum, whether coupons can be combined with insurance, or how supply and shipping will work — those details are not yet known from this reporting.

It is also worth noting what the numbers are compared against. The savings are measured against list prices, which few insured patients pay directly, so the real-world benefit depends heavily on a person's current coverage.

What happens next

The White House says drugs from other manufacturers that have signed MFN deals will be added to TrumpRx.gov "in the coming months" ^[1]. Sixteen deals with major manufacturers have been announced since September 30, 2025 ^[1].

The pricing framework rests on executive action: an executive order signed May 12, 2025, letters to manufacturers on July 31, 2025, and a December 1, 2025 agreement with the United Kingdom to raise net prices there by 25% ^[1]. On January 15, 2026, the president asked Congress to pass "The Great Healthcare Plan," which would write the MFN savings into law ^[1]. Whether Congress acts is unresolved in these sources.